Breaking the Cycle: A Family’s Journey Through Polycystic Kidney Disease
Editor’s Note: Patient Worthy is honored to share this patient story, which comes to us from our partners at PKD-Free Alliance. Polycystic kidney disease (PKD)
PKD Foundation
PKD Foundation
The PKD Foundation is the only organization in the U.S. solely dedicated to finding treatments and a cure for polycystic kidney disease (PKD) and to improving the lives of those it affects. Since 1982, we have proudly funded more than $50 million in PKD research and leveraged $1.5 billion in government funding, while serving our local communities across the country. We are inspired by our mission. And driven by our vision.
Condition Awareness & Advocacy
Here is a list of conditions this partner raises awareness and advocacy for:
Patient Worthy Posts on Polycystic Kidney Disease
Investigational Treatment for ADPKD Earns FDA’s Orphan Drug Designation
Approximately 540,000 individuals in the United States have been diagnosed with autosomal dominant polycystic kidney disease (ADPKD). The disease causes persistent and rapidly accumulating cysts
New Validated Tool Assesses ADPKD Pain
Editor’s Note: We believe that patients are a key part of developing and leading the conversation in disease communities. Patient Worthy sometimes partners with reputable
Cubs Fan with PKD Goes to Wrigley Field in Search of Kidney Donor
When Christine Todd learned that her kidneys were failing, she was frightened and concerned. Todd has polycystic kidney disease (PKD), an inherited condition characterized by
FDA Grants Orphan Drug Designation to Oxypurinol for ADPKD
In February 2023, I spoke with Dr. Allen Davidoff of XORTX Therapeutics Inc. (“XORTX”) about the company’s commitment to developing therapies for people living
Rare Community Profiles: PKD Foundation and IQVIA Partner to Create Next-Gen ADPKD Registry
Rare Community Profiles Rare Community Profiles is a new Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community,
